SCHEMBL14359082

SCHEMBL14359082

CC(C)NC(=O)Nc1ccc(/C=C/c2ccc(N(C)C)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.50
NPC1 O15118 4/20 0.50
NOX1 Q9Y5S8 3/20 0.50
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
TP53 P04637 3/20 0.50
MMP13 P45452 1/20 0.50
ESR2 Q92731 1/20 0.50
EPHX1 P07099 1/20 0.49
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA9 Q16790 2/20 0.49
HSD17B3 P37058 1/20 0.49
APP P05067 1/20 0.47
RECQL P46063 1/20 0.47
KMT2A Q03164 3/20 0.47
NR4A1 P22736 1/20 0.47
LMNA P02545 2/20 0.46
RELA Q04206 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14359085 1.00 MAPT (0.50) MAPTNPC1NOX1RAB9ASMN1; SMN2
SCHEMBL9435958 0.91 MAPT (0.58) MAPTNPC1NOX1RAB9ASMN1; SMN2
SCHEMBL14358579 0.83 NOX1 (0.54) MAPTNPC1NOX1RAB9ASMN1; SMN2
SCHEMBL14358580 0.83 NOX1 (0.54) MAPTNPC1NOX1RAB9ASMN1; SMN2
SCHEMBL14359154 0.82 MAPT (0.53) MAPTNPC1RAB9ASMN1; SMN2MMP13
SCHEMBL14359153 0.82 MAPT (0.53) MAPTNPC1RAB9ASMN1; SMN2MMP13
SCHEMBL14358480 0.82 MMP13 (0.59) MAPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL14358477 0.82 MMP13 (0.59) MAPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL14358669 0.80 MAPT (0.60) MAPTNPC1RAB9ASMN1; SMN2MMP13
SCHEMBL14358667 0.80 MAPT (0.60) MAPTNPC1RAB9ASMN1; SMN2MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2724156-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE The Jackson Laboratory (US) 2014-04-30 EP claimed
CN-103765212-A Methods and compositions for treating cancer and autoimmune diseases JACKSON LAB 2014-04-30 CN claimed
US-20130184342-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE THE JACKSON LABORATORY (US) 2013-07-18 US claimed
WO-2013003112-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE THE JACKSON LABORATORY (US) 2013-01-03 WO claimed
US-10207988-B2 Methods and compositions for treatment of cancer and autoimmune disease THE JACKSON LABORATORY (US) 2019-02-19 US disclosed
EP-2724156-B1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE JACKSON LAB (US) 2017-08-16 EP disclosed
EP-2724156-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE The Jackson Laboratory (US) 2014-04-30 EP disclosed
CN-103765212-A Methods and compositions for treating cancer and autoimmune diseases JACKSON LAB 2014-04-30 CN disclosed
US-20130184342-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE THE JACKSON LABORATORY (US) 2013-07-18 US disclosed
WO-2013003112-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE THE JACKSON LABORATORY (US) 2013-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184342-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE BAK1, SSB, MRE11 MAPT 3931/4885NPC1 3752/4885NOX1 1419/4885
US-10207988-B2 Methods and compositions for treatment of cancer and autoimmune disease BAK1, SSB, MRE11 MAPT 3931/4885NPC1 3752/4885NOX1 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.